Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years

Susanna Esposito, Paola Marchisio, Samantha Bosis, Lara Lambertini, Laura Claut, Nadia Faelli, Ciro Bianchi, Giorgio L. Colombo, Nicola Principi

Research output: Contribution to journalArticlepeer-review


This paper reports the data concerning the net economic cost savings attributable to influenza vaccination in healthy children aged 2-5 years, and may be useful when deciding the best recommendations for the use of influenza vaccine in pediatrics. A total of 303 previously unprimed healthy children aged 2-5 years (163 males; mean age ± S.D.: 3.22 ± 2.43 years) were prospectively, blindly randomised in a 2:1 ratio to receive two doses of an inactivated, trivalent, virosome-formulated subunit influenza vaccine (Inflexal V, Berna Biotech, Berne, Switzerland) or no vaccination. The results show that influenza vaccination of healthy children aged 2-5 years substantially reduces influenza-like illnesses and related costs in the children themselves and their families. However, larger and longer running study spanning multiple seasons may be warranted before suggesting the universal vaccination of this group of subjects.

Original languageEnglish
Pages (from-to)629-635
Number of pages7
Issue number5
Publication statusPublished - Jan 30 2006


  • Children
  • Influenza
  • Influenza vaccination

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)


Dive into the research topics of 'Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years'. Together they form a unique fingerprint.

Cite this